Spectral Medical Inc

EDT on TSXToday's ChangeVolume52 Week Range (Low/Hi)Market Cap
0.37CAN 0.01/1.39%87,1170.20 / 0.5082.42 M

Contact Information

Spectral Medical Inc

Headquarters:
135 The West Mall, Unit 2
Toronto, Ontario
Canada, M9C 1C2
Tel: 416-626-3233
Email: Send a message
Website: Visit website
For more information...
Lead: Shushu Feng

Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.

PMX has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 150,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 350,000 patients are diagnosed with severe sepsis and septic shock in North America each year. Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information please visit www.spectraldx.com.

Paul Walker, M.D., Ph.D., F.R.C.S.C  - Director, President & Chief Executive Officer

Richard Wieland - Chief Financial Officer

Debra M. Foster, B.Sc. (Human Biology) - Vice President, Clinical Development

Dr. Gualtiero Guadagni, Ph.D - Vice President, Sales and Marketing

 

Anthony Bihl - Chairman of the Board

Paul Walker - Director

Kevin Giese - Director

Jun Hayakawa - Director

Guillermo Herrera - Director

William Stevens - Director

Stock Information

Company Overview

Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.

PMX has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 150,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 350,000 patients are diagnosed with severe sepsis and septic shock in North America each year. Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information please visit www.spectraldx.com.

Management

Paul Walker, M.D., Ph.D., F.R.C.S.C  - Director, President & Chief Executive Officer

Richard Wieland - Chief Financial Officer

Debra M. Foster, B.Sc. (Human Biology) - Vice President, Clinical Development

Dr. Gualtiero Guadagni, Ph.D - Vice President, Sales and Marketing

 

Board of Directors

Anthony Bihl - Chairman of the Board

Paul Walker - Director

Kevin Giese - Director

Jun Hayakawa - Director

Guillermo Herrera - Director

William Stevens - Director

Contact Information

Headquarters:
135 The West Mall, Unit 2
Toronto, Ontario
M9C 1C2, Canada
Telephone: 416-626-3233
Email: Send a message
Website: Visit website